|
Patients (n)
|
767
|
106
|
|
Age (years; mean ± SD)
|
54.1 ± 14.9
|
50.5 ± 15.6
|
|
Sex (% female)
|
79.9
|
75.2
|
|
Rheumatoid factor (% positive)
|
55.3
|
78.1
|
|
Disease duration at baseline (mean ± SD)
|
8.1 ± 10.6 years
|
11.5 ± 12.5 weeks
|
|
Duration of follow up (years; mean ± SD; range)
|
-
|
3.2 ± 1.3; 1–7.25
|
|
Disease activity characteristics (median [1st;3rd quartile])
|
At cross-section
|
At baseline
|
|
Swollen joint count (0–28)
|
3 (1;7)
|
7 (4;13)
|
|
Tender joint count (0–28)
|
2 (0;6)
|
8 (3;16)
|
|
ESR (mm; normal <20)
|
23 (14;55)
|
49 (24;70)
|
|
CRP (mg/dl; normal <1.0)
|
1.1 (0.5;2.7)
|
5.1 (1.9;17.0)
|
|
Patient assessment of pain (mm; 0–100)
|
37 (19;53)
|
50 (32;66)
|
|
Patient global assessment of activity (mm; 0–100)
|
37 (18;58)
|
51 (33;66)
|
|
Evaluator global assessment of activity (mm; 0–100)
|
34 (19;49)
|
44 (31;58)
|
|
HAQ (0–3)
|
0.875 (0.25;1.5)
|
0.75 (0;1.5)
|
|
Larsen score
|
-
|
1 (0;7)
|
|
Completeness of data for analysis
| | |
|
Cross-sectional correlation between composite indices (n [%])
|
767/767 (100)a
|
105/106 (99.1%)b
|
|
Cross-sectional correlation with HAQ scores (n [%])
|
720/767 (93.9)
|
104/106 (98.1)b
|
|
Discriminant validity, 1-year follow up (n [%])
|
-
|
91/100 (91.0%)
|
|
Construct validity, 3-year follow upc (n [%])
|
-
|
56/80 (70.0%)
|
